BioMarin Announces Addition of David Pyott, Former Allergan Chairman and CEO, to Company’s Board of Directors
January 04 2016 - 8:30AM
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that
David Pyott has been elected to the company’s board of directors.
Mr. Pyott is the former Chairman and Chief Executive Officer
of Allergan and will join the BioMarin Board effective immediately.
“I am delighted to have David join BioMarin's board of
directors,” said Jean-Jacques Bienaimé, Chairman and Chief
Executive Officer of BioMarin. “He is an accomplished
executive who led Allergan to significant profitability through its
global operations across 100 countries. As BioMarin prepares for
regulatory filings with multiple new molecular entities in 2016,
David’s expertise in organizational scaling will be instrumental as
we pursue the next significant stage of growth for the
Company.”
From 1998 to 2015, Mr. Pyott served as CEO of Allergan, where he
was recognized by the Harvard Business Review as one of “The 100
Best Performing CEO’s in the World.” Under his leadership,
Allergan was transformed from a small eye care business with
approximately $1 billion in sales to a global specialty
pharmaceutical and medical device company, with sales over $7
billion in 2014 and more than 10,000 employees.
Prior to Allergan, Mr. Pyott served as the Head of the Novartis
Nutrition Division and as a member of the Executive Committee of
Switzerland-based Novartis AG. Mr. Pyott is Lead Director and a
member of the Board of Directors of Avery Dennison Corporation, a
member of the Board of Directors of Alnylam Pharmaceuticals,
Inc. and a member of the Supervisory Board of Royal Philips in
the Netherlands. He is Vice Chairman of the Board of Trustees of
Chapman University, a member of the Governing Board of the London
Business School, President of the International Council of
Ophthalmology Foundation, and a member of the Advisory Board of the
Foundation of the American Academy of Ophthalmology. Mr. Pyott
holds a Diploma in International and European Law from the Europa
Institute at the University of Amsterdam, a Master of Arts degree
from the University of Edinburgh, and a Master of Business
Administration degree from the London Business School.
About BioMarin
BioMarin is a global biotechnology company that develops and
commercializes innovative therapies for patients with serious and
life-threatening rare and ultra-rare genetic diseases. The
company's portfolio consists of five commercialized products and
multiple clinical and pre-clinical product candidates. For
additional information, please visit www.BMRN.com.
Contacts:
Investors
Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558
Media
Debra Charlesworth
BioMarin Pharmaceutical Inc.
(415) 455-7451
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024